Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30

$1.96+0.02 (+1.03%)

Close on Nov 13, 2026Market cap $19.56MP/E –Yield –

Atossa Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2015 it was -7431.9%, against 100.0% the year before. The highest annual figure on record is 100.0% in fiscal 2014.

Period	Period end	Value	Change (pts)
FY2015	Dec 31, 2015	-7431.9%	−7531.9
FY2014	Dec 31, 2014	100.0%	+78.3
FY2013	Dec 31, 2013	21.7%	−64.7
FY2012	Dec 31, 2012	86.4%	+6465.7
FY2011	Dec 31, 2011	-6379.3%	–

See a number that looks wrong?